GlassScriptPhysician profile
Catherine L Laughlin
NPI 1114961067
$5,250.07
in general payments reported to CMS, 2019-2025
26 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $259 · 2022: $338 · 2023: $1,175 · 2024: $706 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.35 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,152.23 | 2019-2025 | |
| Janssen Biotech, INC. | $729.85 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $554.14 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $423.22 | 2019-2024 | Winlevi, Absorica Ld |
| Pfizer INC. | $403.31 | 2019-2025 | |
| Lilly USA, LLC | $378.65 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $324.71 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $272.75 | 2023-2024 | Sotyktu |
| Amgen INC. | $213.77 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $130.01 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $111.82 | 2019 | |
| Galderma Laboratories, L.P. | $110.03 | 2019 | |
| Leo Pharma INC. | $94.64 | 2022-2025 | Adbry, Anzupgo |
| Celgene Corporation | $67.74 | 2019 | |
| Prugen, INC. Pharmaceuticals | $46.74 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.61 | 2019 | |
| Dermavant Sciences, INC. | $29.75 | 2023-2024 | Vtama |
| Dermira, INC. | $28.75 | 2019 | |
| Merck Sharp & Dohme LLC | $24.50 | 2019 | |
| Mayne Pharma Commercial LLC | $20.25 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.95 | 2019 | |
| Genentech USA, INC. | $15.97 | 2019 | |
| Incyte Corporation | $15.83 | 2023 | Opzelura |
| Sandoz INC. | $15.68 | 2019 | |
| Kerecis Limited | $13.95 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.